RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Guillain-Barré Syndrome: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Disseminated intravascular large B-cell lymphoma initially presenting as polyradiculoneuropathy, mimicking Guillain-Barré syndrome
Seungjin Choi et al., Annals of Clinical Neurophysiology (16 October 2026)
https://doi.org/10.14253/acn.26008
- 2.
Before Guillain-Barré syndrome is attributed to a Zika infection, the presence of flavivirus RNA must be confirmed by PCR.
Scorza Fulvio et al., Tropical doctor (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42885714/
- 3.
Viral triggers of Guillain-Barré syndrome: implications for laboratory diagnostics.
Kłodnicka Karolina et al., Biochemia medica (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42828225/
- 4.
Dermatomyositis with Acute Motor-Sensory Axonal Neuropathy Variant of Guillain-Barré Syndrome: A Rare Coexistence
, International Journal of Drug Delivery Technology (14 October 2026)
https://doi.org/10.25258/ijddt.16.67s.87
- 5.
Zika Virus Infection: A Possible Cause in the Development of Guillain-Barré Syndrome?
Priya Suresh, Open Collections (13 October 2026)
https://doi.org/10.14288/ujemip.v4.203739
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Guillain-Barré Syndrome
Guillain-Barré Syndrome is a rare neurological disorder in which the immune system mistakenly attacks the peripheral nervous system, causing rapidly progressing muscle weakness that can lead to paralysis. It affects approximately 300 Australians each year. Most people recover fully, though recovery can take months and some have lasting effects.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Guillain-Barré Syndrome?
Guillain-Barré Syndrome is a rare neurological disorder in which the immune system mistakenly attacks the peripheral nervous system, causing rapidly progressing muscle weakness that can lead to paralysis. It affects approximately 300 Australians each year. Most people recover fully, though recovery can take months and some have lasting effects.
How many clinical trials are available for Guillain-Barré Syndrome?
RareWays currently indexes 35 clinical trials for Guillain-Barré Syndrome, of which 4 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Guillain-Barré Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Guillain-Barré Syndrome.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.